Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback